ADAG vs. CLRB, EBS, DMAC, IOBT, ANIX, CLSD, ORMP, BTAI, ALLK, and PMVP
Should you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Cellectar Biosciences (CLRB), Emergent BioSolutions (EBS), DiaMedica Therapeutics (DMAC), IO Biotech (IOBT), Anixa Biosciences (ANIX), Clearside Biomedical (CLSD), Oramed Pharmaceuticals (ORMP), BioXcel Therapeutics (BTAI), Allakos (ALLK), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical preparations" industry.
Cellectar Biosciences (NASDAQ:CLRB) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership.
Cellectar Biosciences received 222 more outperform votes than Adagene when rated by MarketBeat users. However, 78.26% of users gave Adagene an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
In the previous week, Cellectar Biosciences had 2 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Cellectar Biosciences and 2 mentions for Adagene. Cellectar Biosciences' average media sentiment score of 1.54 beat Adagene's score of 0.41 indicating that Adagene is being referred to more favorably in the news media.
Cellectar Biosciences' return on equity of 0.00% beat Adagene's return on equity.
16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 4.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Adagene has higher revenue and earnings than Cellectar Biosciences.
Cellectar Biosciences has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Adagene has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.
Cellectar Biosciences currently has a consensus price target of $20.00, indicating a potential upside of 517.28%. Adagene has a consensus price target of $5.00, indicating a potential upside of 135.85%. Given Adagene's higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Adagene.
Summary
Adagene beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks.
Get Adagene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
